OneSource and BRL announce licensing agreement on advanced biologics delivery technology

New Delhi: OneSource Specialty Pharma Limited has forged a strategic licensing agreement with Bhami’s Research Laboratory (BRL).

This partnership grants OneSource access to BRL’s HILOPRO® formulation technology, designed to facilitate the subcutaneous delivery of high-concentration biologic therapies.

The technology aims to reduce viscosity, making it easier to deliver high-concentration biologic products, including monoclonal antibodies and fusion proteins. 

Under the terms of the agreement, OneSource will leverage BRL’s cutting-edge formulation technology to enhance its development and manufacturing services for both drug products and substances. OneSource, renowned for its capabilities in biologics, complex injectables, drug-device combination products, and soft gelatin capsules, operates five state-of-the-art cGMP facilities. The company has a global customer base and an impeccable compliance record, having successfully passed inspections by major health agencies, including the USFDA and EU authorities.

Neeraj Sharma, Managing Director of OneSource, expressed, “We are excited to partner with Bhami’s Research Laboratory, marking a significant step forward for OneSource in enhancing the subcutaneous delivery of high-concentration biologic therapies. This collaboration underscores our commitment to leveraging innovative technologies to address critical challenges in biopharmaceutical development. BRL’s formulation technology offers promising capabilities to reduce viscosity and enable effective delivery of a wide spectrum of biologic products.”

 “The adoption of subcutaneous delivery for small-volume, low-viscosity biotherapeutics offers substantial benefits to patients compared to traditional intravenous injections, including improved healthcare accessibility, reduced hospitalization requirements, and lower overall treatment costs. This technology platform also complements our strong and demonstrated experience in biologics drug substance and drug delivery devices such as auto-injectors and pens. We are looking forward to offering this technology to our existing and prospective customers, across innovative biologic and biosimilar products,” he noted.

Dr. Surya Pai, Co-founder and Chief Executive Officer of BRL, echoed Sharma’s sentiments, saying, “We are pleased to announce our collaboration with OneSource, a distinguished specialty pharma pure-play CDMO, to expand the accessibility of our advanced subcutaneous protein delivery platform. This partnership represents a significant advancement in our commitment to enhancing biologic therapy delivery. Our globally patented high-concentration, low-viscosity protein drug delivery platform aims to optimize patient care by offering convenient, affordable, and safe treatment options. Together with OneSource, we look forward to setting new benchmarks in biopharmaceutical innovation and improving healthcare outcomes worldwide.”